Matt Gonda, CEO of Amytrx Therapeutics

Two years post-stealth ex­it, high­ly se­cre­tive in­flam­ma­tion biotech se­cures fi­nal tranche of Se­ries A round

Back in Sep­tem­ber 2020, a tiny biotech emerged from stealth out of Nashville, call­ing it­self Amytrx Ther­a­peu­tics and pur­su­ing chron­ic in­flam­ma­tion. By all mea­sures, the biotech has been ex­treme­ly qui­et — pub­lish­ing on­ly one press re­lease an­nounc­ing its stealth ex­it.

Now, it’s got its next one.

The biotech an­nounced Wednes­day that it closed the fi­nal tranche of its Se­ries A round, which to­tals $18 mil­lion to ex­pand on clin­i­cal re­search for AMTX-100, its an­ti-in­flam­ma­to­ry pep­tide drug can­di­date that is be­ing re­searched for a va­ri­ety of in­flam­ma­to­ry in­di­ca­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.